



ASX ANNOUNCEMENT

6 July 2026

Board Update

Sydney, Australia, 6 July 2026: Chimeric Therapeutics (ASX: CHM) (**Chimeric** or the **Company**), a leading Australian cell therapy company, advises that Mr Eric Sullivan, Independent Non-executive Director, has notified the Board of his decision to retire from the Board.

Mr Sullivan joined the Chimeric Board in August 2023 and has during his tenure served as Chairman of the Audit and Risk Committee and as a Member of the Remuneration and Compensation Committee. Mr Sullivan has resigned for personal reasons and accordingly this will take effect immediately.

Mr Bradley Glover, Chairman of the Company, thanked Mr Sullivan for his service over the period.

The full Board will now perform the function of the Audit and Risk Committee until further notice.

Authorised on behalf of the Chimeric Therapeutics by the Board of Directors.

For more information:

Corporate Enquiries

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au